Reni Benjamin
Stock Analyst at Citizens
(1.14)
# 3,820
Out of 5,241 analysts
165
Total ratings
37.68%
Success rate
-11.72%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Downgrades: Market Perform | n/a | $0.494 | - | 1 | Mar 13, 2026 | |
| IMMX Immix Biopharma | Initiates: Market Outperform | $23 | $8.99 | +155.84% | 1 | Mar 9, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.94 | +157.73% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $1.83 | +446.45% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $4.36 | +175.23% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $105.80 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $60 | $21.38 | +180.64% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $250 → $50 | $3.92 | +1,175.51% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $95.19 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $7.50 | - | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $12 → $4 | $0.4953 | +707.59% | 5 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.86 | +39.86% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.44 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $8.36 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $8.38 | +19.33% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $3 → $6 | $4.34 | +38.25% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $34.48 | -33.29% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.04 | +64.47% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.20 | +204.35% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.13 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $16.02 | +149.69% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.39 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $12.94 | -38.18% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $47.85 | +25.39% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.46 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $128.88 | +144.41% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $75.08 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $212.87 | +24.49% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.53 | +381.59% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $5.65 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.35 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $39.48 | -69.60% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.58 | - | 1 | Nov 15, 2017 |
Immutep
Mar 13, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.494
Upside: -
Immix Biopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $23
Current: $8.99
Upside: +155.84%
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $1.94
Upside: +157.73%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $1.83
Upside: +446.45%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $4.36
Upside: +175.23%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $105.80
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $21.38
Upside: +180.64%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $250 → $50
Current: $3.92
Upside: +1,175.51%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $95.19
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.50
Upside: -
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.4953
Upside: +707.59%
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.86
Upside: +39.86%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $8.36
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $8.38
Upside: +19.33%
Mar 11, 2026
Maintains: Market Outperform
Price Target: $3 → $6
Current: $4.34
Upside: +38.25%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $34.48
Upside: -33.29%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.04
Upside: +64.47%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.20
Upside: +204.35%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.13
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $16.02
Upside: +149.69%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.39
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $12.94
Upside: -38.18%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $47.85
Upside: +25.39%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.46
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $128.88
Upside: +144.41%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $75.08
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $212.87
Upside: +24.49%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.53
Upside: +381.59%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $5.65
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $4.35
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $39.48
Upside: -69.60%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $28.58
Upside: -